Skip to main content

Table 7 Increase in the relative frequency (%), relative to placebo, in different outcomes, the corresponding number needed to treat (NNT) and 95% CIs calculated using a normal approximation. - Data were not available. Data from different studies were pooled when the same outcomes from the same treatments were available and when they referred to doses and/or regimens approved in Brazil

From: The Brazilian Society of Rheumatology guidelines for axial spondyloarthritis – 2019

Outcome PASI50 PASI75 PASI90
Follow-up time (weeks)
24 24 24
Drug % NNT (95% CI) % NNT (95% CI) % NNT (95% CI)
Infliximab [195] 66.7 1.5 (1.3–1.8) 58.8 1.7 (1.4–2.1) 38.4 2.6 (2.0–3.6)
Etanercept [196, 197] 27.0 3.7 (2.6–6.3) 20.8 4.8 (3.5–7.8)
Adalimumab [198] 62.5 1.5 (1.2–1.8) 58.8 1.7 (1.4–2.2) 41.7 2.4 (1.9–3.3)
Golimumab [199] 66.7 1.5 (1.3–1.8) 55.5 1.8 (1.6–2.2) 32.2 3.1 (2.4–4.3)
Certolizumab pegol [200] 45.5 2.2 (1.7–2.9) 45.5 2.2 (1.8–2.8) 35.7 2.8 (2.2–3.7)
Secukinumab [201, 202] 37.0 2.1 (1.8–2.6) 35.7 2.7 (2.2–3.4)